Key facts
- MarvelBiome’s last known valuation is $204.6M (Oct 2025).
- It has raised $44.9M across 4 recorded rounds; the latest was Early Stage VC ($39.6M) in Oct 2025.
- Notable investors include C2I Accelerator, DRADS Capital, Thomvest Ventures.
- MarvelBiome has filed 3 Form Ds with the SEC since 2020, most recently Aug 2023 ($10.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for MarvelBiome
Funding rounds
4 roundsAbout MarvelBiome
Operator of a biopharmaceutical technology company intended to harness the power of microbes for treating various human diseases. The company's technologies are focused on isolating, identifying, and characterizing microbial populations for novel therapeutic applications, enabling researchers to get assistance in assay methods.
- Sector
- Healthcare
- HQ
- Woburn, MA, United States
- Founded
- 2019
- Website
- marvelbiome.com/
- Ownership
- Privately Held (backing)
MarvelBiome doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MarvelBiome shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MarvelBiome in its N-PORT filings yet. We sweep new filings monthly.